Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Clinical trial NCT04191616 · COMPLETED

Trial details

NCT number: NCT04191616
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed or Refractory Multiple Myeloma

Start date: 2020-08-06
Primary completion: 2022-11-30
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.